Modality
Small Molecule
MOA
CAR-T CD19
Target
MET
Pathway
JAK/STAT
PBCDravet
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Sep 2028
Phase 1Current
NCT07572853
927 pts·PBC
2021-10→2028-09·Terminated
927 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-012.4y awayInterim· PBC
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Termina…
Catalysts
Interim
2028-09-01 · 2.4y away
PBC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07572853 | Phase 1 | PBC | Terminated | 927 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| Elracapivasertib | Kymera | Phase 3 | PRMT5 |